Kitov Pharma Revenue, Profits - KTOV Annual Income Statement

Add to My Stocks
$1.72 $0.03 (1.71%) KTOV stock closing price Sep 21, 2018 (Closing)

Fundamental analysis of KTOV stock involves analyzing its financial statements, apart from checking the Kitov Pharma stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement for KTOV which shows a YOY revenue decline of 0 is specific to a period of time. Investors typically check YoY or QoQ revenue growth. The Kitov Pharma profit and loss statement for 2017 shows a net profit of $-12.27M. Profits for last year was $-12.12M. Apart from this an investor should also check Kitov Pharma assets and Kitov Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Jan - Dec20172016201520142013
Kitov Pharma Revenues or Net Sales
-----
Cost Of Goods Sold (COGS)-----
Kitov Pharma Gross Profit
-----
Research & Development Expense4.64M4.18M2.56M3.19M-
Selling General & Admin Expense7.42M3M1.5M1.98M2.44M
Income Before Depreciation Depletion Amortization-12.06M-7.18M-4.06M-5.18M-2.55M
Depreciation Depletion Amortization-----
Non Operating Income-0.92M-4.88M---
Interest Expense-----
Kitov Pharma Pretax Income
-13M-12.12M-4.2M-5.25M-2.62M
Provision for Income Taxes-----
MinorityInterest-0.73M----
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-13M-12.12M-4.2M-5.25M-2.62M
Extraordinary Items & Discontinued Operations-----
Kitov Pharma Profit/ Loss (Net Income)
-12.27M-12.12M-4.2M-5.25M-2.62M
Average Shares used to compute Diluted EPS9.46M5.76M---
Average Shares used to compute Basic EPS9.46M5.76M---
Income Before Nonrecurring Items-12.27M-12.13M-4.2M--
Income from Nonrecurring Items-----
Kitov Pharma Earnings Per Share Basic Net
-1.30-2.20-4.36--
Kitov Pharma Earnings Per Share Diluted Net
-1.30-2.20-4.36--
EPS Diluted Before Nonrecurring Items-1.30-2.20-4.36--
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Kamada financial analysis

It is very helpful to read a report on Kitov Pharma stock analysis. An investor must check the following items in an income statement:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Kitov Pharma revenue chart implies that the company is growing. It has not been the case with Kitov Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-12.27M for KTOV stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the KTOV income statement, one can check the Kitov Pharma historical stock prices to check how the price has moved with time.

Kitov Pharma Income Statement - Key Financial Ratios

Annual Income Statements - Kitov Pharmaceuticals Holdings Ltd (ADR) Industry Peers

Compugen income statement, IsoRay income statement, Kamada income statement, RENEURON GP PLC income statement, XTL Biopharma income statement